Cardiac Amyloidosis, Pacemaker
Conditions
Brief summary
This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.
Interventions
OTHERPacemaker Rate
CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.
Sponsors
University of Minnesota
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults 18 and older * Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee * Implanted Cardiac Pacemaker (+/- Defibrillator) * Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation * Non-dilated left ventricle by echocardiography * Ability to provide written consent * English Speaking
Exclusion criteria
* Paced QRS duration of \>150 ms (indicator for pacing mediated dyssynchrony) * Dilated left ventricle
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Kansas City Cardiomyopathy Questionnaire Score | Month 4 | 75-100 representing good to excellent health, and 0-24 representing very poor to poor health |
| Composite of any cardiovascular event | Month 4 | admission or urgent visit for heart failure and atrial fibrillation, myocardial infarction or stroke |
Countries
United States
Contacts
CONTACTMeghan Muscala
PRINCIPAL_INVESTIGATORValmiki Maharaj
University of Minnesota
Outcome results
None listed